Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Universitë De Bordeaux

Gamamabs Pharma Sa

Laboratoire Franais Du Fractionnement Et Des Biotechnologies

Philippe Mondon

Abdelhakim Kharrat

Khalil Bouayadi

Christian Behrens

Alexandre Fontayne

Sylvie Jorieux

Celine Monnet-Mars

Christophe De Romeuf

Abdessatar Chtourou

Christel Larbouret

Andre Pelegrin

Thierry Chardes

Olivier Dubreuil

Cyril Lorenzato

Gisèle Clofent-Sanchez

Céline Monnet

Yassamine Lazrek

Jeanny Laroche-Traineau

Céline Monnet-Mars

Nadege A Gaborit

Audrey Hémadou

Martine Cérutti

Marie-Josée Jacobin-Valat

The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.

Use of modified Fc fragments in immunotherapy

Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.

Fc mutants with modified functional activity

A specific binding molecule is provided which binds to galectin-3 protein, methods of their production and methods of use.

Specific binding molecule directed against galectin-3 protein

A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.

Optimized FC variants

The invention relates to antibodies against HER3 and their use in the treatment of cancer.

Antibodies against HER3

Growing community of inventors

Neuve Chapelle, France

Philippe Mondon